CRISPR Therapeutics has some promising and innovative pipeline candidates. The stock will soar if it can execute and deliver strong clinical and regulatory progress. CRISPR Therapeutics has lagged the ...

Casgevy is starting to build some serious sales momentum. CRISPR Therapeutics also has a deep pipeline and healthy funding. The stock requires patience, but there is a visible path to a bright future.

After teasing a new regulatory process for personalized genetic medicines at the end of last year, the FDA today unveiled draft guidance for an approval pathway that could see custom CRISPR therapies, ...

I was born in Washington, DC, in 1964, the oldest of three sisters, but the place that truly formed me as a scientist was Hilo, on the Big Island of Hawaii. Growing up there, far from the mainland ...